Premium
Calcium hydroxylapatite for jawline rejuvenation: consensus recommendations
Author(s) -
Dallara JeanMarie,
Baspeyras Martine,
Bui Patrick,
Cartier Hugues,
Charavel MarieHélène,
Dumas Laurent
Publication year - 2014
Publication title -
journal of cosmetic dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.626
H-Index - 44
eISSN - 1473-2165
pISSN - 1473-2130
DOI - 10.1111/jocd.12074
Subject(s) - hydroxylapatite , facial rejuvenation , rejuvenation , medicine , calcium , surgery , dentistry , chemistry , biochemistry , enzyme
Summary Background Age‐associated volume loss is now known to play an important role in the structural changes of the aging face. In the lower face, this manifests as drooping of the corners of the mouth and jowl leading to a loss of the oval jawline of youth. Jawline reshaping by replacing volume has therefore become an indispensable component of modern facial rejuvenation. Aim Calcium hydroxylapatite (CaHA; Radiesse ® , Merz Pharmaceuticals GmbH, Frankfurt, Germany) is an injectable filler with a cosmetic indication for tissue augmentation. The ability of calcium hydroxylapatite to provide immediate and long‐lasting volume enhancement makes it an ideal agent for restoring an oval jawline. Method This consensus statement has been developed to assist clinicians who would like to gain more experience in the use of volumizing agents to achieve an optimal outcome with this procedure. Results Using the recently developed Merz Aesthetics Scale ® for jawline, the consensus provides a treatment protocol for individuals at each stage of oval loss and presents a series of before and after images to illustrate the improvements that can be achieved. Specific recommendations for calcium hydroxylapatite including type of anesthesia, injection techniques, volume for injection, use in combination with other procedures, and expected duration of corrections are provided. Techniques for minimizing and managing expected problems and potential complications are also described. Conclusion Calcium hydroxylapatite is appropriate for treating patients at any stage of oval loss.